Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Negative regulation-resistant p53 variant enhances oncolytic adenoviral gene therapy.

Human gene therapy - 1 Jun 2012

Koo Taeyoung, Choi Il-Kyu, Kim Minjung, Lee Jung-Sun, Oh Eonju, Kim Jungho, Yun Chae-Ok

Abstract excerpt

Intact p53 function is essential for responsiveness to cancer therapy. However, p53 activity is attenuated by the proto-oncoprotein Mdm2, the adenovirus protein E1B 55kD, and the p53 C-terminal domain. To confer resistance to Mdm2, E1B 55kD, and C-terminal negative regulation, we generated a p53 variant (p53VPΔ30) by deleting the N-terminal and C-terminal regions of wild-type p53 and inserting the transcriptional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Down-Regulation
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Vectors

Share to Mice, Nude

Share to Microscopy, Electron, Transmission

Share to Transcriptional Activation

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 22248367
DOI: 10.1089/hum.2011.114
PMCID: PMC3392620

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Negative regulation-resistant p53 variant enhances oncolytic adenoviral gene therapy.PMID 22248367Read ↗

Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment.Semantic proximity Read ↗

Advances in adenovirus-mediated p53 cancer gene therapySemantic proximity Read ↗

Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene TherapySemantic proximity Read ↗

Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncologySemantic proximity Read ↗

Inhibition of nonsense-mediated decay rescues functional p53β/γ isoforms in MDM2-amplified cancersSemantic proximity Read ↗

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectivesSemantic proximity Read ↗

Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.Semantic proximity Read ↗

TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19Semantic proximity Read ↗

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.Semantic proximity Read ↗

Adenovirus p53 gene therapySemantic proximity Read ↗

Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation.Semantic proximity Read ↗

Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.